Expansions - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Expansions

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 3, Issue 1
Ravensburg, Germany (Jan. 23)Vetter Pharma-Fertigung GmbH & Co. KG (www.vetter-pharma.com) received a manufacturing license for its new Ravensburg Vetter South plant. The automated production facility will provide single-chamber cartridges, dual-chamber syringes and cartridges, and fill liquid and lyophilized vials.

Wilmington, DE (Jan. 22)AstraZeneca (www.astrazeneca.com) will invest $100 million to expand its Waltham, Massachusetts facility by 132,000 ft2 to boost infectious-disease and cancer research. The expanded facility will accommodate roughly 100 additional researchers who will join the more than 400 current discovery employees.

St. Petersburg, FL (Jan. 17)Dermazone Solutions, Inc. (www.dermazonesolutions.com) introduced its new contract-manufacturing division, dermaCM (www.dermacm.com), and its topical pharmaceutical and cosmeceutical manufacturing and development facility. dermaCM will offer formulation, private labeling, manufacturing, packaging, and fulfillment services.

Shanghai, China (Jan. 16)WuXi PharmaTech (www.pharmatechs.com), a provider of pharmaceutical research and development outsourcing services, began moving the first group of scientists to its new Tianjin research facility. The new facility complements the Shanghai research campus with 130,000 ft2 of laboratory space.

Leverkusen, Germany (Jan. 16)Lanxess (www.lanxess.com) earmarked EUR 30 million to develop its fine-chemicals subsidiary Saltigo (www.saltigo.com). The money will go toward modernizing Saltigo's plant and introducing new worktime models. A EUR 10-million multipurpose facility also is under construction.

Morton Grove, IL (Jan. 6)Regis Technologies, Inc. (www.registech.com) added supercritical fluid chromatography (SFC) to its separations services and will offer GMP separations starting April 1, 2007. Regis will offer SFC as a stand-alone service or in concert with its GMP manufacturing.

Parsippany, NJ (Jan. 3)DSM Pharmaceuticals (www.dsmpharmaceuticals.com) completed an expansion to its sterile parenteral manufacturing facility in Greenville, North Carolina. The expansion adds a clinical-trial materials manufacturing suite that is capable of manufacturing large- and small-molecule liquid and lyophilized products.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here